Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement a Phase 2 trial of its lead multiple sclerosis drug candidate, Lucid-MS. The agreement, announced by NEWMEDIAWIRE, moves the experimental treatment from planning into execution and sets up a rigorous clinical test of a novel approach to MS.
Most existing MS therapies work by suppressing or modulating the immune system to reduce attacks on the central nervous system. Lucid-MS is designed around a different mechanism: a proprietary platform that aims to protect the nerve’s own insulation, known as myelin, by targeting demyelination directly rather than solely quieting immune activity. If successful, this neuroprotective strategy could offer an alternative for patients who do not respond adequately to current immune-focused treatments.
The partnership with Thermo Fisher’s clinical research business, a leading global contract research organization with deep expertise in central nervous system and MS studies, lends operational credibility to the program. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed the agreement to cover implementation of the Phase 2 trial, which will test Lucid-MS in patients with MS. The trial’s launch marks a critical milestone for the company, as Phase 2 studies are typically designed to assess both safety and early signs of efficacy.
Why this matters extends beyond one company’s pipeline. Multiple sclerosis affects millions worldwide, and while immune-modulating drugs have transformed care, many patients still experience disease progression. A therapy that specifically targets demyelination could complement or even challenge the dominant treatment paradigm. By enlisting Thermo Fisher’s clinical research business, Quantum BioPharma is signaling that it intends to generate robust data capable of withstanding regulatory scrutiny. Read More about the agreement and its implications for the MS treatment landscape.
Investors and patients alike will watch the Phase 2 trial closely. Success would validate not only Lucid-MS but also the broader concept of neuroprotection as a viable strategy in MS. Conversely, failure would underscore the difficulty of translating preclinical promise into clinical benefit. For now, the Study Start-Up Agreement transforms Lucid-MS from a promising candidate into an actively tested therapy. The company’s latest news and updates are available in its newsroom at https://ibn.fm/QNTM, and full terms of use and disclaimers for the content provided by IBN can be found at https://IBN.ai/Disclaimer. The original release can be viewed on www.newmediawire.com.
